Last reviewed · How we verify
NCT04524078: LLETIS
Lleida TIA Intervention Study
NA trial testing intensive integrated intervention care program in Transient Ischemic Attack in 100 participants. Completed in 31 March 2020.
1 March 2020
Quick facts
| Lead sponsor | Institut de Recerca Biomèdica de Lleida |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 100 |
| Start date | 1 March 2011 |
| Primary completion | 1 March 2020 |
| Estimated completion | 31 March 2020 |
Drugs / interventions tested
- intensive integrated intervention care program
Conditions studied
- Transient Ischemic Attack — all drugs for Transient Ischemic Attack →
Sponsor
Institut de Recerca Biomèdica de Lleida
Who can join
18 and older, any sex, with Transient Ischemic Attack. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Having a transient ischemic attack (TIA) or a minor stroke is a real risk factor not only for early recurrent stroke but also for major extracranial vascular events. Despite these warning events provide an opportunity for prevention usual post-discharge care of these subjects (mainly at primary care) is not associated with an optimal control of cerebrovascular risk factors (CRF). The investigators hypothesized that patients exposed to the intensified integrated multifactorial interventional care program (ICP) model would exhibit better management of CRF and receive more targeted advice than patients receiving standard care. A second objective was to investigate the effect of the ICP model on stroke recurrence or the appearance of major extracranial vascular events. To test this hypothesis the investigators perform a controlled, randomized, single blind, parallel trial. Subjects are recruited at the Stroke Unit and are randomized into two groups: 1. usual care (control group) and 2. ICP (intervention group). Patients assigned to receive usual care (general practitioner with the possibility of being referred to specialists) are compared to those assigned to undergo ICP. This ICP involves strict treatment goals (LDL-cholesterol \<100 mg/dl, blood pressure \<130/80 mmHg, HbA1c\<7%, no smoking, regular exercise and no excessive alcohol consumption) to be achieved through behavior modification (diet, physical activity, smoking cessation, alcohol cessation) and a stepwise introduction of pharmacologic therapy for the main CRF (hypercholesterolemia, hypertension and diabetes). This multifactorial intervention is overseen in each primary care center by a trained general practitioner and nursery. The treatment goals are the same for the control group and the intervention group. General practitioners caring patients of each group are informed of these strict treatment goals. Patients in the ICP group receive a minimum of four scheduled individual consultations in one year (baseline, 3, 6 and 9 months). Primary and secondary outcomes are evaluated by an external Neurologist at 12 months after their inclusion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04524078
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transient Ischemic Attack
Currently open trials in the same condition.
- NCT07242768 — Follow-up Extension Study of Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis · recruiting
- NCT06615726 — Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis · Phase 3 · active not recruiting
- NCT06515392 — TIA Scores' Mortality Predictions and Recurrent TIA and Stroke Prediction · recruiting
- NCT06653348 — Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke · Phase 2, PHASE3 · recruiting
- NCT06091319 — Florbetaben for Imaging of Vascular Amyloid · recruiting
Other Institut de Recerca Biomèdica de Lleida trials
Trials by the same sponsor.
- NCT06226194 — Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery · recruiting
- NCT06083363 — Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding · recruiting
- NCT04746157 — A Nursing Support Intervention-based Project for Stroke Survivors · NA · completed
- NCT03375762 — REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT) · NA · unknown
- NCT03791008 — Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04524078 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Recerca Biomèdica de Lleida
- Last refreshed: 24 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04524078.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing